GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual MeetingOstarine Improved Lean Body Mass and Muscle Performance in Patients with Cancer CachexiaWASHINGTON, June 11, 2009 - (Business Wire) - GTx, Inc. (Nasdaq: GTXI - News) today announced...
baseline
body
cachexia
cancer
climb
clinical
gtx
lbm
lean
loss
mass
mk-2866
muscle
ostarine
patients
phase
placebo
results
significant
statistically
study
subject
test
treatment
trial
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.